Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

Recruiting

Phase 1

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

Sponsor:

IRIS Research and Development, LLC

Code:

NCT06581562

Conditions

Rheumatoid Arthritis

Pemphigus Vulgaris

Granulomatosis With Polyangiitis

Systemic Lupus Erythematosus

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AB-101

Rituximab

Cyclophosphamide

Fludarabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-25. This information was provided to ClinicalTrials.gov by IRIS Research and Development, LLC on 2024-09-03.